The public conversation about Ozempic is almost exclusively about weight. Which makes sense — semaglutide is classified as an anti-obesity medication, marketed around satiety, and its most visible effects are physical. The before-and-after photos are weight photos. The clinical trials measured kilograms. The moral panic around it is about bodies.
But the pharmacology keeps leaking out of its lane.
People on GLP-1 receptor agonists have been reporting, anecdotally and then in studies, that their cravings for alcohol diminish. That gambling impulses soften. That certain compulsive behaviours — the reaching, the urge-without-object — seem to quiet down alongside the appetite for food. And now, in a study published this month in the journal Criminology, researchers at Rutgers University have found that current users of GLP-1 medications show a 62% weaker link between impulsivity and violent behaviour, and a 52% weaker connection between alcohol use and violence compared to former users — though the researchers note this second figure showed more variance in sensitivity testing than the impulsivity finding.
Violence. That’s not a weight metric.
How this drug actually works
GLP-1 — glucagon-like peptide-1 — is a hormone produced naturally in the gut after eating. Its role in the digestive system is well understood: it signals satiety, slows gastric emptying, moderates insulin. The drugs that mimic it, semaglutide (Ozempic, Wegovy) foremost among them, were developed to exploit that function.
What was less anticipated was what happens when GLP-1 reaches the brain. GLP-1 receptors are distributed widely across the central nervous system — including in the ventral tegmental area, the nucleus accumbens, and the prefrontal cortex. These are not digestive structures. They are the core of the dopaminergic reward system: the circuitry that drives motivation, craving, compulsion, and habit.
When GLP-1 agonists activate receptors there, something interesting happens. The reward value of various stimuli — food, alcohol, drugs, certain kinds of novelty — appears to decrease. Not through sedation or suppression of pleasure across the board, but through a specific quieting of the “wanting” signal. The urge that precedes the act. The pull before the reach.
A 2025 review carries the title “Curbing the Appetites and Restoring the Capacity for Satisfaction” — language that, if you think about it for a moment, is doing a lot more than describing weight loss.
The addiction angle
Researchers studying addiction have been watching GLP-1 drugs with considerable interest. The overlap between the reward circuits involved in compulsive eating and those involved in substance use disorders is not coincidental — it’s structural. GLP-1 receptors in the nucleus accumbens modulate the dopamine release that underlies craving regardless of what the craving is for.
Animal studies on alcohol, cocaine, and opioid self-administration have shown consistent reductions when GLP-1 agonists are administered. Human data is catching up. The anecdotes have been building for long enough that researchers are now running dedicated addiction trials for semaglutide — not as a weight loss drug used adjacently, but as a direct intervention for substance use disorders.
I find the logic here genuinely interesting. Not because it’s a miracle cure — it clearly isn’t, and the mechanisms are still being untangled — but because of what it implies. If the same receptor pathway mediates your craving for a meal, a drink, and a hit, then “appetite” was never just about food. The word was always a placeholder for something more fundamental: the brain’s wanting machinery. The system that generates drive toward reward, regardless of what the reward is.
The aggression finding and what it complicates
The violence data is the strangest and most philosophically productive piece of this. The Rutgers study, published in June 2026, found that GLP-1 users showed significantly weakened links between impulsivity and violent behaviour, and between alcohol use and violent behaviour. The researchers are cautious — this is observational, not a randomised controlled trial, and the sample of current users was small.
But if the finding holds and replicates, it suggests that GLP-1 agonists are somehow modulating the impulsive end of the aggression pathway. Which raises a question I keep returning to: if appetite and aggression share enough neural architecture that a single class of drug appears to dampen both, then what does that tell us about the relationship between hunger and violence?
These are not obviously related drives. We’ve spent a long time treating them as separate psychological categories. Appetite belongs to nutrition science and eating disorders. Aggression belongs to criminology and psychiatry. They have different clinicians, different intervention frameworks, different moral registers. GLP-1 doesn’t appear to have received that memo.
What appetite actually was
The more useful frame might be this: appetite is not a single drive with multiple objects. It is the brain’s general wanting capacity — the mechanism that generates directed motivation toward something that has previously been rewarding, or that the brain predicts will be rewarding. Food, sex, alcohol, substances, social status, certain kinds of conflict — these are all objects the reward system can attach to.
A drug that quiets that wanting system would, in principle, reach all of them. Not equally, not uniformly, and not without side effects (the evidence on GLP-1s and mood, including some signals around depression, remains under active scrutiny — anyone currently using GLP-1 medications should discuss any mood changes with their prescriber). But structurally, a drug that acts on the nucleus accumbens is not a diet pill that happens to also touch addiction. It is an intervention in the wanting architecture of the human brain that happens to have been packaged and approved as a diet pill.
That’s a different thing. And I think it deserves a different conversation — not a breathless one, but a more honest and precise one than “Ozempic helps you eat less.”
Sovereign Mind lens
This is exactly the kind of problem that calls for careful epistemic framing: when a cultural narrative about a drug, a behaviour, or a human impulse hardens into a frame that prevents us from asking the questions the evidence is already raising.
- Unlearning: The category of “appetite” as a distinct, food-specific drive is an inherited assumption that neuroscience no longer supports cleanly. Similarly, the framing of Ozempic as a weight loss drug — and only that — is a commercial and regulatory artifact, not a biological fact. What would change about how we think about cravings, compulsion, and even aggression if we started from the reward circuitry first, rather than from the behaviour?
- Restoration: The cognitive conditions for examining this clearly require slowing down a media cycle that moves from clinical finding to lifestyle trend in days. Much of what is being reported about GLP-1 and behaviour is preliminary, contested, and incomplete. The restoration impulse here is to resist the pressure to have a settled view — and to hold the uncertainty as the most honest available position while the science matures.
- Defense: Both the moral panic around Ozempic and the uncritical enthusiasm for it are manipulation vectors. The panic frames the drug as an attack on human authenticity, willpower, or embodied experience. The enthusiasm uses emerging behavioural data to position it as a civilisational solution. Both are ahead of the evidence. Recognising that neither narrative is the science — and that the actual research is messier and more interesting than either — is a form of intellectual self-protection.
An open question
I’m not arguing that GLP-1 drugs are good or bad, or that we should expand their use to include criminal justice applications, or that the Rutgers study means anything definitive about violence prevention. The researchers themselves are clear about the limitations.
What I’m interested in is the question these findings force: if the same neural pathway underlies wanting food, wanting a drink, and the kind of impulsive reactivity that tips into aggression — what does that mean for how we understand desire itself? What does it mean that we’ve been treating these as separate moral and medical categories when they appear, at the receptor level, to be expressions of the same underlying system?
That’s not a question Ozempic answers. But it’s one that Ozempic, unexpectedly, has started to ask.
